Scientists investigate enzyme link to panic disorder

NCT ID NCT07424911

Completed Knowledge-focused Sponsor: Elazığ Mental Health and Diseases Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study looked at levels of a specific enzyme, α-N-acetylgalactosaminidase, in the blood of people with panic disorder who had never taken medication. Researchers compared these levels to healthy individuals and checked for connections with symptom severity and inflammation. The goal was to better understand the biology behind panic disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could point toward a biological marker for panic disorder, potentially aiding future diagnosis or treatment.
What could go wrong: This is a small, early observational study, not a treatment trial. The enzyme may not prove to be a reliable marker, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANIC DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

panic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANIC DISORDER

Contacts and locations

Show contact details

Locations

Mehmet Hamdi ÖRÜM

Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.